'Global Bio-Medical Forum 2010 (GBF 2010)' co-organized by KOTRA and the Korean Bio-association and sponsored by the Ministry of Knowledge Economy will be held at the COEX on June 28-29.
150 companies in biotechnology, pharmaceutical, medical device manufacturers from 31 countries and 350 domestic companies will participate in the event and have one to one consultation talks. KOTRA expects over 800 consultations will be made through this event.
As it is the 3rd year for the event, the size of participating buyers and the domestic companies has increased compared to last year. The 10 global pharmaceutical companies including Johnson & Johnson, Roche and a number of prominent companies such as DuPont, Ranbaxy, Medtronic and others will be there. Until last year, the event focused on pharmaceutical and biotechnology sectors but since the medical device sector added from this year, the event puts together the entire medical industry.
According to KOTRA, the buyers said, "This is the opportunity to discover Korea's outstanding R & D achievements." Domestic companies showed their interest in the event by saying, "Perfect chance to meet Global companies."
One of the global pharmaceutical companies, Roche, who participated in this event last year, has concluded transfer agreements worth USD 300 million with Korean company, Digital Biotec. This is regarded as a successful case, the first agreement in the Asian region excepting Japan.
For 2 days of the conference, discussions about 12 detailed subjects such as promising technologies in Korea, demand for business cooperation with Korea and others will be conducted by 66 speakers from foreign companies.
At the same time, 'Frontier Research and Support Centers,' which support the commercialization of R & D achievements as part of National research and development projects will introduce 8 major research achievements including in the 'new autoimmune disease drug' and explore the ways for various technical cooperation including technology transfer, joint research.
An official from KOTRA said, "This is a significant event to seek an overseas expansion for high-value medical technology and biotechnology industries." This event undertakes various projects to support for the superior technology and global technical cooperation.
SOURCE: KOTRA